{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:52:53Z","timestamp":1786708373132,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["BMGF#OPP1134599"],"award-info":[{"award-number":["BMGF#OPP1134599"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Accurate reporting of antiretroviral therapy (ART) uptake is crucial for measuring the success of epidemic control. Programs without linked electronic medical records are susceptible to duplicating ART initiation events. We assessed the prevalence of undisclosed ART use at the time of treatment initiation and explored its correlates among people presenting to public ambulatory clinics in South Africa. Data were analyzed from the community-based delivery of ART (DO ART) clinical trial, which recruited people living with HIV who presented for ART initiation at two clinics in rural South Africa. We collected data on socioeconomic factors, clinical factors, and collected blood as part of study screening procedures. We estimated the proportion of individuals presenting for ART initiation with viral load suppression (&lt;\u200920 copies\/mL) and fitted regression models to identify social and clinical correlates of non-disclosure of ART use. We also explored clinical and national databases to identify records of ART use. Finally, to confirm surreptitious ART use, we measured tenofovir (TDF) and emtricitabine (FTC) levels in dried blood spots. A total of 193 people were screened at the two clinics. Approximately 60% (n\u2009=\u2009114) were female, 40% (n\u2009=\u200978) reported a prior HIV test, 23% (n\u2009=\u200944) had disclosed to a partner, and 31% (n\u2009=\u200961) had a partner with HIV. We found that 32% (n\u2009=\u200962) of individuals presenting for ART initiation or re-initiation had an undetectable viral load. In multivariable regression models, female sex (AOR 2.16, 95% CI 1.08\u20134.30), having a prior HIV test and having disclosed their HIV status (AOR 2.48, 95% CI 1.13\u20135.46), and having a partner with HIV (AOR 1.94, 95% CI 0.95\u20133.96) were associated with having an undetectable viral load. In records we reviewed, we found evidence of ART use from either clinical or laboratory databases in 68% (42\/62) and detected either TDF or FTC in 60% (37\/62) of individuals with an undetectable viral load. Undisclosed ART use was present in approximately one in three individuals presenting for ART initiation or re-initiation at ambulatory HIV clinics in South Africa. These results have important implications for ART resource use and planning in the region. A better understanding of reasons for non-disclosure of ART at primary health care clinics in such settings is needed.<\/jats:p>","DOI":"10.1007\/s10461-021-03319-4","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T07:04:57Z","timestamp":1623049497000},"page":"3695-3703","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Undisclosed Antiretroviral Therapy Use at Primary Health Care Clinics in Rural KwaZulu Natal South Africa: A DO-ART Trial Sub-study"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2090-3453","authenticated-orcid":false,"given":"Nsika","family":"Sithole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Resign","family":"Gunda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Koole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meighan","family":"Krows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torin","family":"Schaafsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mosa","family":"Moshabela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Siedner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Celum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruanne V.","family":"Barnabas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"key":"3319_CR1","first-page":"1","volume-title":"Joint United Nations Program on HIV\/AIDS (UNAIDS). UNAIDS data 2017","author":"UNAIDS","year":"2017","unstructured":"UNAIDS. Joint United Nations Program on HIV\/AIDS (UNAIDS). UNAIDS data 2017. Geneva: UNAIDS; 2017. p. 1\u2013248."},{"key":"3319_CR2","volume-title":"Joint United Nations Program on HIV\/AIDS (UNAIDS)","author":"UNAIDS","year":"2019","unstructured":"UNAIDS. Joint United Nations Program on HIV\/AIDS (UNAIDS). Geneva: UNAIDS; 2019."},{"key":"3319_CR3","unstructured":"https:\/\/www.unaids.org\/en\/resources\/documents\/2020\/unaids-data. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2020_aids-data-book_en.pdf"},{"key":"3319_CR4","volume-title":"Joint United Nations Programme on HIV\/AIDS. Ambitious treatment targets: writing the final chapter of the AIDS epidemic","author":"UNAIDS","year":"2014","unstructured":"UNAIDS. Joint United Nations Programme on HIV\/AIDS. Ambitious treatment targets: writing the final chapter of the AIDS epidemic. Geneva: UNAIDS; 2014."},{"issue":"1","key":"3319_CR5","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1186\/s12889-015-2179-2","volume":"15","author":"AB Kharsany","year":"2015","unstructured":"Kharsany AB, Cawood C, Khanyile D, et al. Strengthening HIV surveillance in the antiretroviral therapy era: rationale and design of a longitudinal study to monitor HIV prevalence and incidence in the uMgungundlovu District, KwaZulu-Natal, South Africa. BMC Public Health. 2015;15(1):1149.","journal-title":"BMC Public Health"},{"issue":"4","key":"3319_CR6","doi-asserted-by":"publisher","first-page":"S469","DOI":"10.1097\/QAD.0000000000000480","volume":"28","author":"J Larmarange","year":"2014","unstructured":"Larmarange J, Bendaud V. HIV estimates at second subnational level from national population-based surveys. AIDS. 2014;28(4):S469.","journal-title":"AIDS"},{"issue":"1","key":"3319_CR7","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1186\/s12879-017-2740-y","volume":"17","author":"H Huerga","year":"2017","unstructured":"Huerga H, Shiferie F, Grebe E, et al. A comparison of self-report and antiretroviral detection to inform estimates of antiretroviral therapy coverage, viral load suppression and HIV incidence in Kwazulu-Natal, South Africa. BMC Infect Dis. 2017;17(1):653\u2013653.","journal-title":"BMC Infect Dis"},{"issue":"10","key":"3319_CR8","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1093\/infdis\/jit390","volume":"208","author":"JM Fogel","year":"2013","unstructured":"Fogel JM, Wang L, Parsons TL, et al. Undisclosed antiretroviral drug use in a multinational clinical trial (HIV prevention trials network 052). J Infect Dis. 2013;208(10):1624\u20138.","journal-title":"J Infect Dis"},{"issue":"2","key":"3319_CR9","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1097\/QAI.0b013e3182a2db02","volume":"65","author":"EM Kahle","year":"2014","unstructured":"Kahle EM, Kashuba A, Baeten JM, et al. Unreported antiretroviral use by HIV-1-infected participants enrolling in a prospective research study. J Acquir Immune Defic Syndr. 2014;65(2):e90\u20134.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"17","key":"3319_CR10","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1097\/QAD.0000000000001227","volume":"30","author":"AA Kim","year":"2016","unstructured":"Kim AA, Mukui I, Young PW, et al. Undisclosed HIV infection and antiretroviral therapy use in the Kenya AIDS indicator survey 2012: relevance to national targets for HIV diagnosis and treatment. AIDS. 2016;30(17):2685\u201395.","journal-title":"AIDS"},{"issue":"11","key":"3319_CR11","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1097\/QAD.0000000000001862","volume":"32","author":"S Moyo","year":"2018","unstructured":"Moyo S, Gaseitsiwe S, Powis KM, et al. Undisclosed antiretroviral drug use in Botswana: implication for national estimates. AIDS. 2018;32(11):1543\u20136.","journal-title":"AIDS"},{"issue":"5","key":"3319_CR12","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1097\/QAD.0000000000002147","volume":"33","author":"BE Hoots","year":"2019","unstructured":"Hoots BE, Wejnert C, Martin A, et al. Undisclosed HIV infection among MSM in a behavioral surveillance study. AIDS. 2019;33(5):913\u20138.","journal-title":"AIDS"},{"issue":"8","key":"3319_CR13","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1007\/s10461-018-2351-7","volume":"23","author":"J Manne-Goehler","year":"2019","unstructured":"Manne-Goehler J, Rohr J, Montana L, et al. ART denial: results of a home-based study to validate self-reported antiretroviral use in rural South Africa. AIDS Behav. 2019;23(8):2072\u20138.","journal-title":"AIDS Behav"},{"issue":"10","key":"3319_CR14","doi-asserted-by":"publisher","first-page":"e1305","DOI":"10.1016\/S2214-109X(20)30313-2","volume":"8","author":"RV Barnabas","year":"2020","unstructured":"Barnabas RV, Szpiro AA, van Rooyen H, et al. Community-based antiretroviral therapy versus standard clinic-based services for HIV in South Africa and Uganda (DO ART): a randomised trial. Lancet Glob Health. 2020;8(10):e1305\u201315.","journal-title":"Lancet Glob Health"},{"issue":"2","key":"3319_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/QAI.0b013e31822866a2","volume":"58","author":"K Sukapirom","year":"2011","unstructured":"Sukapirom K, Onlamoon N, Thepthai C, et al. Performance evaluation of the alere PIMA CD4 test for monitoring HIV-infected individuals in resource-constrained settings. JAIDS J Acquir Immune Defic Syndr. 2011;58(2):141\u20137.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"1","key":"3319_CR16","doi-asserted-by":"publisher","first-page":"e000014","DOI":"10.1136\/tsaco-2016-000014","volume":"1","author":"AJ Carden","year":"2016","unstructured":"Carden AJ, Salcedo ES, Tran NK, et al. Prospective observational study of point-of-care creatinine in trauma. Trauma Surg Acute Care Open. 2016;1(1):e000014\u2013e000014.","journal-title":"Trauma Surg Acute Care Open"},{"issue":"4","key":"3319_CR17","first-page":"617","volume":"50","author":"LA Cole","year":"2012","unstructured":"Cole LA. The hCG assay or pregnancy test. Clin Chem Lab Med CCLM. 2012;50(4):617\u201330.","journal-title":"Clin Chem Lab Med CCLM"},{"issue":"1","key":"3319_CR18","doi-asserted-by":"publisher","first-page":"18908","DOI":"10.7448\/IAS.17.1.18908","volume":"17","author":"M Osler","year":"2014","unstructured":"Osler M, Hilderbrand K, Hennessey C, et al. A three-tier framework for monitoring antiretroviral therapy in high HIV burden settings. J Int AIDS Soc. 2014;17(1):18908\u201318908.","journal-title":"J Int AIDS Soc"},{"issue":"3","key":"3319_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.7196\/SAMJ.7598","volume":"104","author":"G Sherman","year":"2014","unstructured":"Sherman G, Lilian R, Bhardwaj S, et al. Laboratory information system data demonstrate successful implementation of the prevention of motherto-child transmission programme in South Africa. S Afr Med J. 2014;104(3):235\u20138.","journal-title":"S Afr Med J"},{"key":"3319_CR20","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.15.20103226","author":"MJ Siedner","year":"2020","unstructured":"Siedner MJ, Kraemer JD, Meyer MJ, et al. Access to primary healthcare during lockdown measures for COVID-19 in rural South Africa: a longitudinal cohort study. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.05.15.20103226.","journal-title":"medRxiv"},{"key":"3319_CR21","volume-title":"Bioanalytical method validation. Guidance for industry","author":"Food and Drug Administration","year":"2018","unstructured":"Food and Drug Administration. Bioanalytical method validation. Guidance for industry. Washington DC: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine; 2018."},{"issue":"8","key":"3319_CR22","doi-asserted-by":"publisher","first-page":"865","DOI":"10.4155\/bio.12.44","volume":"4","author":"G Smith","year":"2012","unstructured":"Smith G. European medicines agency guideline on bioanalytical method validation: what more is there to say? Bioanalysis. 2012;4(8):865\u20138.","journal-title":"Bioanalysis"},{"issue":"5","key":"3319_CR23","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1093\/ije\/dym211","volume":"37","author":"F Tanser","year":"2008","unstructured":"Tanser F, Hosegood V, B\u00e4rnighausen T, et al. Cohort profile: Africa centre demographic information system (ACDIS) and population-based HIV survey. Int J Epidemiol. 2008;37(5):956\u201362.","journal-title":"Int J Epidemiol"},{"issue":"4","key":"3319_CR24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/QAI.0000000000002036","volume":"81","author":"K Brittain","year":"2019","unstructured":"Brittain K, Mellins CA, Remien RH, Phillips TK, Zerbe A, Abrams EJ, et al. Impact of HIV-status disclosure on HIV viral load in pregnant and postpartum women on antiretroviral therapy. J Acquir Immune Defic Syndr. 2019;81(4):379\u201386.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"3319_CR25","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2105\/AJPH.2007.123257","volume":"98","author":"RC Goldsworthy","year":"2008","unstructured":"Goldsworthy RC, Schwartz NC, Mayhorn CB. Beyond abuse and exposure: framing the impact of prescription-medication sharing. Am J Public Health. 2008;98(6):1115\u201321.","journal-title":"Am J Public Health"},{"key":"3319_CR26","first-page":"4","volume":"20","author":"A Boulle","year":"2019","unstructured":"Boulle A, Heekes A, Tiffin N, et al. Data centre profile: the provincial health data centre of the Western Cape Province, South Africa. Int J Popul Data Sci. 2019;20:4.","journal-title":"Int J Popul Data Sci"},{"issue":"1","key":"3319_CR27","first-page":"44","volume":"40","author":"WR Truong","year":"2015","unstructured":"Truong WR, Schafer JJ, Short WR. Once-daily, single-tablet regimens for the treatment of HIV-1 infection. P T Peer Rev J Formul Manag. 2015;40(1):44\u201355.","journal-title":"P T Peer Rev J Formul Manag"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-021-03319-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-021-03319-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-021-03319-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T03:17:28Z","timestamp":1635823048000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-021-03319-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["3319"],"URL":"https:\/\/doi.org\/10.1007\/s10461-021-03319-4","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,7]]},"assertion":[{"value":"22 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study received ethics approval from the University of KwaZulu\u2019s Biomedical Research. Ethics Committee. Protocol reference number: BREC\/00001227\/2020.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}